Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FABP2 | P12104 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24210462 | 0.82 | SLC6A2 (0.43) | RAPGEF4PTGS2MEN1TSHRKMT2A | |
| SCHEMBL84476 | 0.80 | LMNA (0.44) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL16105634 | 0.80 | CES2 (0.44) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL8352425 | 0.80 | CES2 (0.44) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL28193191 | 0.77 | CES2 (0.45) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL3518451 | 0.76 | CES2 (0.41) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL17553267 | 0.76 | CES2 (0.41) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL1585297 | 0.76 | ADRB2 (0.50) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL23422374 | 0.76 | CES2 (0.41) | CES2CES1APPPDPK1AKR1C3 | |
| SCHEMBL1318569 | 0.76 | CES2 (0.50) | CES2CES1APPPDPK1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| US-10336775-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| CN-107108601-A | Glycosidase inhibitor | 阿森纽荣股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CES2 4143/4885CES1 3778/4885APP 2909/4885 |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CES2 2785/4885CES1 327/4885APP 4408/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885APP 37/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CES2 2722/4885CES1 317/4885APP 4440/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885APP 37/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885APP 37/4885 |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CES2 2722/4885CES1 317/4885APP 4440/4885 |
| US-10336775-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885APP 37/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885APP 37/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | CES2 2722/4885CES1 317/4885APP 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.